CAR-T therapy, a promising treatment for blood cancer, involves reengineering immune cells and has shown high remission rates. Currently expensive in Brazil, a collaboration aims to locally produce CAR-T treatments, potentially reducing costs to $35,000 per dose. This initiative could lead to significant cost savings and wider accessibility for patients.







